Pleco Therapeutics aims to extend the life span and enhance the quality of life of patients through its novel Plecoid™ therapies that dramatically increase the effectiveness of current cancer treatments.
Pleco Therapeutics’ mission is to demonstrate the market value and therapeutic potential of our proprietary Plecoid™ products through an initial focus on treatments for orphan cancers. Thereafter we can expand our scalable fixed-dose combination platform for the treatment of other cancers as well as neurodegenerative disorders where aberrant metal patterns have been shown to play a role.
Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.